Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Cefuroxime Axetil
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Sandoz B2B
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Through this transaction, Sandoz has acquired rights to three established brands (Zinnat, Zinacef and Fortum) in more than 100 markets, further reinforcing its leading global position in antibiotics.
Product Name : Zinnat
Product Type : Antibiotic
Upfront Cash : Undisclosed
November 10, 2021
Lead Product(s) : Cefuroxime Axetil
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Sandoz B2B
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Cefuroxime Axetil
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Sandoz B2B
Deal Size : $500.0 million
Deal Type : Divestment
GSK to Sell Cephalosporin Antibiotics Business to Sandoz
Details : Cephalosporin manufacturing will transfer from GSK sites to Sandoz following a four-year manufacturing and supply agreement (MSA) and subsequent transfer of manufacturing operations.
Product Name : Zinnat
Product Type : Antibiotic
Upfront Cash : Undisclosed
November 02, 2021
Lead Product(s) : Cefuroxime Axetil
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Sandoz B2B
Deal Size : $500.0 million
Deal Type : Divestment
Lead Product(s) : Cefuroxime Axetil
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Efficacy of Cefecin Tab. in Patients With Acute Sinusitis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 11, 2020
Lead Product(s) : Cefuroxime Axetil
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cefuroxime Axetil
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Undisclosed
Sponsor : Eurasia Invest | Ministry of Education and Science, Kazakhstan
Deal Size : Inapplicable
Deal Type : Inapplicable
The Sublimated Mare Milk Supplement's Effect on Gut Mucosal Lining After Antibiotics
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 05, 2018
Lead Product(s) : Cefuroxime Axetil
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Undisclosed
Sponsor : Eurasia Invest | Ministry of Education and Science, Kazakhstan
Deal Size : Inapplicable
Deal Type : Inapplicable